The mechanism for such an in situ conversion of TAs into a vaccine is illustrated in Figure 1A, according to the following steps: Step 1—Vaccinating tumor cells presenting α-gal epitopes bind the natural anti-Gal IgM and IgG antibody molecules and activates the complement system. Here, GAL is linked to neoplasm.